You are here: Industry Insights > Intas

News List

Intas enters into agreement with Meiji and Dong-A ST to commercialise DMB-3115 expresspharma
July 23, 2021
Under the terms of the agreement, Intas has been granted exclusive licence rights to commercialise DMB-3115 worldwide, excluding Japan, Korea and certain countries in Asia.
Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab) prnasia
July 22, 2021
Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive license agreement with Meiji and Dong-A Socio Holdings (a parent company of Dong-A ST) to commercialize ...
Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States prnasia
March 05, 2021
Foresee Pharmaceuticals announced that it has entered into an exclusive license agreement with Intas Pharmaceuticals for the US commercialization of Foresee's novel FP-001 program, Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use ...
Intas gets DCGI nod for clinical trials of hyperimmune globulin for COVID-19 treatment expresspharma
August 27, 2020
It can be an important therapeutic option that can potentially help combat the disease until a vaccine is available, states the company.
Intas launches trastuzumab biosimilar to treat breast cancer firstwordpharma
April 11, 2019
Intas Pharmaceuticals announced Wednesday that it launched its trastuzumab biosimilar, under the brand name Eleftha, in India, reported Business Standard.